OpenLobby.EU
Explore

BEAM Alliance

BEAM Alliance is a European group representing small businesses developing treatments for antimicrobial resistance.

Lobbying Activity

Meeting with Boriša Falatar (Cabinet of Commissioner Hadja Lahbib)

2 Dec 2025 · MCM strategy

Meeting with Annukka Ojala (Cabinet of Executive Vice-President Roxana Mînzatu)

14 Nov 2025 · Europe’s health preparedness

BEAM Alliance demands IVDR reforms to support AMR diagnostics

6 Oct 2025
Topic — A consultation on simplifying EU rules for medical and in vitro diagnostics.
Message — The group requests streamlining requirements to reduce regulatory costs and delays for innovative products. They advocate for a central expert group and more professionalised Notified Bodies with standardised costs.123
Why — Reducing compliance burdens would make these SMEs more attractive to investors.45
Impact — Notified Bodies would lose pricing autonomy and confidentiality of their internal processes.67
Read full response

Response to European Innovation Act

3 Oct 2025

BEAM Alliance represents 70+ European SMEs developing 120+ innovative products against antimicrobial resistance (AMR). AMR already causes 35,000 deaths in Europe and economic impacts that amount to billions, and these figures will continue to grow. BEAM aims to improve R&D environment to help curb the AMR threat, because the field continues to face a severe innovation gap, and one of the central causes is the persistent lack of access to adequate fundingboth public and privateat all stages of research, development, and commercialization. Public funding remains an indispensable driver of progress in this area, particularly because AMR is a broken market where private capital is chronically scarce. Yet, the way current funding mechanisms are structured often excludes or disadvantages the small and mid-sized enterprises (SMEs) that constitute the backbone of AMR innovation. Large-scale consortia calls under programmes such as Horizon Europe or the Innovative Health Initiative (IHI), while valuable, impose disproportionate administrative burdens on smaller firms and divert resources away from their primary scientific and technological activities. To correct this imbalance, more targeted opportunities for single-entity applications, such as those offered through the European Innovation Council (EIC), should be expanded and simplified. ARPA-style funding with streamlined application processes could further enable high-impact projects to progress without unnecessary procedural hurdles. At the same time, the evaluation of funding proposals must adopt a more pragmatic approach. Too often, priority is given to projects that appear futuristic on paper, despite their limited feasibility or practical necessity. A rebalancing is needed so that ambitious but realistic innovationsthose capable of delivering tangible outcomes and real-world market impactreceive appropriate recognition and support. In this context, technology readiness level (TRL) requirements should remain flexible, allowing companies to justify their funding needs across both early-stage discovery and later-stage development. Furthermore, ambition should not be measured by the size of a projects budget; current thresholds, such as the European Investment Banks minimum of 10 million, exclude many pioneering firms that require smaller but still significant investments (e.g. diagnostics development), often in the range of 5 million. Additionally, the definition of an undertaking in difficulties should be revised: biotech firms frequently accumulate debt as a normal part of their growth trajectory without being at genuine risk of insolvency, yet this classification unfairly blocks them from national grants and tax credits. Greater clarity in defining what constitutes a startup, a scaleup, or an innovative company would improve the precision of fund targeting. Areas of high unmet medical need and systemic market failure, such as AMR, should also receive urgent and specific attention. On the private side, Europe continues to lag behind global peers in mobilizing investment to sustain AMR innovation. While late-stage growth capital is important, it should not be developed at the expense of early-stage funding, which remains particularly lacking in AMR and innovators continuously struggle to attract risk-tolerant capital. Incentives are urgently needed to stimulate greater private participationfor example, through national tax credits for contributions to investment funds, with explicit inclusion of early-stage funds. Equally, persistent barriers to cross-border investments must be eliminated to allow capital to flow more freely within the European market. Without such reforms, promising AMR companies risk stalling before they can demonstrate value or scale their innovations, perpetuating the dangerous gap between scientific potential and the tools available to address one of the most pressing public health challenges of our time.
Read full response

Meeting with Alexandra Hild (Cabinet of Commissioner Ekaterina Zaharieva), Ann-Sofie Ronnlund (Cabinet of Commissioner Ekaterina Zaharieva)

26 Sept 2025 · EU innovation policy and Horizon Europe

Meeting with Tiemo Wölken (Member of the European Parliament)

4 Apr 2025 · General exchange on health policy

Meeting with Stine Bosse (Member of the European Parliament) and Novo Nordisk Foundation and AMR Action Fund GP, LLC

28 Mar 2025 · Setting up event on AMR

Meeting with Stine Bosse (Member of the European Parliament) and Novo Nordisk Foundation and AMR Action Fund GP, LLC

28 Feb 2025 · Setting up event on AMR

Meeting with Stine Bosse (Member of the European Parliament) and Novo Nordisk Foundation and AMR Action Fund GP, LLC

31 Jan 2025 · European health policy

Meeting with Adam Jarubas (Member of the European Parliament, Committee chair)

13 Dec 2024 · Antybiotykooporność w UE

Meeting with András Tivadar Kulja (Member of the European Parliament)

4 Dec 2024 · AMR

Meeting with Tomislav Sokol (Member of the European Parliament) and AbbVie and

17 Oct 2024 · Health policy

Meeting with Stine Bosse (Member of the European Parliament, Committee chair)

27 Sept 2024 · European health policy

Meeting with Tiemo Wölken (Member of the European Parliament)

17 Apr 2024 · AMR (staff level)

Meeting with Tilly Metz (Member of the European Parliament, Shadow rapporteur)

11 Mar 2024 · Pharmaceutical legislation

Meeting with Pernille Weiss-Ehler (Member of the European Parliament, Rapporteur)

3 Nov 2023 · Directive on Medicinal products for human use

Meeting with Tomislav Sokol (Member of the European Parliament, Shadow rapporteur) and AbbVie and

25 Oct 2023 · Pharmaceutical legislation

Meeting with Tiemo Wölken (Member of the European Parliament, Rapporteur)

3 Aug 2023 · Revision of the Pharmaceutical Legislation (staff level)

Meeting with Pierre Delsaux (Director-General Health Emergency Preparedness and Response Authority)

8 Jun 2023 · Discussions on push incentives models for antibiotics

Meeting with Pernille Weiss-Ehler (Member of the European Parliament)

15 May 2023 · Resolution on EU action to combat antimicrobial resistance

Meeting with Annukka Ojala (Cabinet of Commissioner Stella Kyriakides), Karolina Herbout-Borczak (Cabinet of Commissioner Stella Kyriakides)

29 Jun 2022 · VTC meeting on Revision of the pharmaceutical legislation and Anti-microbial resistance.

Response to Recommendation for strengthened actions against antimicrobial resistance

24 Mar 2022

The BEAM Alliance thanks the European Commission for the possibility to provide feedback on the Antimicrobial resistance- recommendation for greater action initiative. Inappropriate use of antimicrobial agents across human, animal, and environmental sectors accelerates the rise of antimicrobial resistance (AMR). AMR is threatening the achievement of Sustainable Development Goals (SDGs) and is already considered the silent global pandemic. As we learned from the COVID-19 crisis, preparedness is key to avoid the AMR pandemic which is getting out of control. Since microbes are continuously evolving, we will always need new innovative products to tackle the problem of AMR. The measures proposed by the 2018 OECD report “Stemming the superbug tide – Just a few dollars more” (1) are very important because they can prevent a health tidal wave. Tackling the problem from a “One Health” perspective is also important, if only to consider that 70% of antibiotics are consumed by animals and that there is little innovation in this sector. Better support could therefore also reduce the selection pressure for microbial resistance and, in turn, have a positive impact on human health. All these related measures may be useful to narrow down the focus of where exactly efforts in innovation will need to be placed to find solutions, making the process more efficient and less expensive. But, again, we will always need new AMR products. As a consequence, the Recommendation must promote the development and marketing of AMR products, whether for prevention, diagnosis or therapy. And because of the market failure faced in the AMR field, new incentives are needed. It seems that Member States’ core concern today is related to availability and access to existing antimicrobials, both innovative and old ones. The former are often not launched in EU Member States due to lack of commercial viability, while the latter face shortages issues. We need to find a sustainable pathway for access to existing antimicrobials, but also for new innovative products to reach the market. In our recent reflection paper (bit.ly/3AKLpzn), we argue that the most effective approach is to combine a Europe-wide instrument that rewards innovation (like a Transfer Exclusivity Extension voucher) with one or more instruments that ensure access at national level. The Recommendation could encourage such approach and promote cooperation and coordination between Member States in the design of such national tool(s), building for example on the experience gained by Sweden during its ongoing pilot subscription period. The Recommendation could also promote the establishment of indicators to monitor the dynamism of innovation in this area, such as the diversity of approaches in the product portfolio, the diversity of targeted pathogens, the adaptation of regulatory paths for new approaches, etc. In general, the Recommendation should encourage Member States to do more, and especially to do more quickly, especially in terms of encouraging innovation. To date, Member States have developed their national plans and strategies to tackle AMR but they do not adequately address the level of innovation and access support still needed. For this it appears many Member States are relying on the European Commission to make proposals. It is time for them to take part in the construction of the (regulatory) framework that will enable Europe and the world to keep the threat of AMR at bay. (1): https://www.oecd.org/health/stemming-the-superbug-tide-9789264307599-en.htm
Read full response

Meeting with Pierre Delsaux (Director-General Health Emergency Preparedness and Response Authority)

18 Jan 2022 · To discuss HERA

Response to Evaluation and revision of the general pharmaceutical legislation

27 Apr 2021

The BEAM Alliance welcomes the European Commission’s intention to modify the EU Pharmaceutical legislation. As far as the antimicrobial resistance (AMR) field is concerned, the revision should lay down the foundation for a more attractive market that allows SMEs, the main innovation engine in the AMR field, to operate in comparable way to other therapeutic fields. Because AMR products have a broad range supporting place in modern medicine, and because they bring benefit not only to infected patients but to the whole community, they should benefit from specific incentives in return. Financial incentives are needed to re-create an investment-friendly environment for research and innovation. Regulatory incentives are needed to not only simplify registration process across Europe but also to enable a fair evaluation of a new product’s performance and clinical utility. Solutions at EU level are needed to improve the ability of SMEs to survive and reach the market. More details are provided in our supporting document.
Read full response

Meeting with Annukka Ojala (Cabinet of Commissioner Stella Kyriakides)

1 Oct 2020 · Virtual meeting about the Antimicrobial Resistance

Meeting with Eszter Batta (Cabinet of Commissioner Thierry Breton)

11 Sept 2020 · Challenges faced by EU SME in the anti-microbial resistance field and the upcoming pharmaceutical strategy.